2022 Annual Meeting | C65 - Core Principles of Brain Tumors

Date Monday 04/04/22

Time 07:00 AM - 09:00 AM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Nimish A. Mohile, MD, FAAN

Topic(s) Neuro-oncology

Learning Objectives Participants should receive a primer on the classification, oncologic multi-disciplinary treatment, neurologic care, supportive and palliative care for patients with adult gliomas. Faculty will provide an update on tumor classification, an overview of principles of oncologic treatment, and updates regarding recent clinical trials. Management of neurologic and medical complications will be discussed in addition to principles of palliative care.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:10 AM PDT	Speaker	Classification of Adult Brain Tumors: WHO 2021 Nimish A. Mohile, MD, FAAN
07:00 AM - 07:00 AM PDT	Speaker	walk in slides Nimish A. Mohile, MD, FAAN
07:10 AM - 07:50 AM PDT	Speaker	Treatment of Adult-type Gliomas Jennie W. Taylor, MD
07:50 AM - 08:20 AM PDT	Speaker	Medical and Neurologic Care of Patients with Brain Tumors Nimish A. Mohile, MD, FAAN
08:20 AM - 08:50 AM PDT	Speaker	Palliative and Supportive Care for Patients with Brain Tumors Katherine B. Peters, MD, PhD, FAAN
08:50 AM - 09:00 AM PDT	Q&A	Discussion and Questions Nimish A. Mohile, MD, FAAN, Jennie W. Taylor, MD, Katherine B. Peters, MD, PhD, FAAN

Faculty Disclosures
Nimish A. Mohile, MD, FAAN	The institution of Dr. Mohile has received research support from Novocure.
Jennie W. Taylor, MD	Dr. Taylor has received personal compensation for serving as an employee of Servier. The institution of Dr. Taylor has received research support from BMS. The institution of Dr. Taylor has received research support from Servier. The institution of Dr. Taylor has received research support from Navio. Dr. Taylor has received research support from University of Colorado. Dr. Taylor has received research support from Mt Sinai University . Dr. Taylor has received publishing royalties from a publication relating to health care.
Katherine B. Peters, MD, PhD, FAAN	Dr. Peters has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Servier. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sapience. Dr. Peters has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NuVox Therapeutics. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ONO Pharmaceutical. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Telix. Dr. Peters has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AnHeart. Dr. Peters has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Rigel. The institution of Dr. Peters has received research support from Biomimetix. The institution of Dr. Peters has received research support from Servier. The institution of Dr. Peters has received research support from Varian. The institution of Dr. Peters has received research support from Sapience. The institution of Dr. Peters has received research support from Ono Pharmaceuticals.

��ɫ��

��ɫ��